243 related articles for article (PubMed ID: 12469696)
1. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation.
Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696
[TBL] [Abstract][Full Text] [Related]
2. [Anti-Pseudomonas aerosol therapy in cystic fibrosis: improvement with tobramycin].
Foucaud P; Borel B; Charara O; Nathanson S; Petitprez P; Pin I
Rev Pneumol Clin; 2002 Jun; 58(3 Pt 1):131-8. PubMed ID: 12486796
[TBL] [Abstract][Full Text] [Related]
3. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
[TBL] [Abstract][Full Text] [Related]
4. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
Mordasini C; Aebischer CC; Schoch OD
Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
6. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
7. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
8. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
9. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Gappa M; Steinkamp G; Tümmler B; von der Hardt H
Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515
[TBL] [Abstract][Full Text] [Related]
10. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
Stelmach I; Korzeniewska A; Stelmach W
Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
[TBL] [Abstract][Full Text] [Related]
12. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
13. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Chuchalin A; Amelina E; Bianco F
Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
[TBL] [Abstract][Full Text] [Related]
14. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
15. Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
Ryan G; Mukhopadhyay S; Singh M
Cochrane Database Syst Rev; 2003; (3):CD001021. PubMed ID: 12917897
[TBL] [Abstract][Full Text] [Related]
16. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
Berlana D; Llop JM; Manresa F; Jódar R
Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
[TBL] [Abstract][Full Text] [Related]
17. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Hodson ME; Gallagher CG; Govan JR
Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
[TBL] [Abstract][Full Text] [Related]
18. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Ratjen F
Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
[TBL] [Abstract][Full Text] [Related]
19. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
20. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.
Murphy TD; Anbar RD; Lester LA; Nasr SZ; Nickerson B; VanDevanter DR; Colin AA
Pediatr Pulmonol; 2004 Oct; 38(4):314-20. PubMed ID: 15334509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
